Molecule testing and diagnostics firm Quanterix Corporation has secured $46 million in Series D funding from both new and existing investors, adding to the $54 million it's raised in previous rounds. The Lexington, MA-based company has recently said it would consider an IPO and there are crossover investors named in the latest round, but it did not discuss any immediate plans to go public in its latest release. A spokesperson for the firm told FierceBiotech: "While the company has not defined a specific timetable for an IPO, it is under consideration based on the company's rapid growth. More specifics will be provided later in the year as plans are further refined." The new money will go towards the launch of desktop instruments in 2017 as well as the development of 60 new assays by the end of the year, while also looking to further its global reach. It currently focuses on oncology, neurology, inflammation, immunology, cardiac and infectious diseases. Report